Biotricity, Inc. (BTCY)
| Market Cap | 6.67M -31.6% |
| Revenue (ttm) | 15.45M +16.5% |
| Net Income | -4.70M |
| EPS | -0.18 |
| Shares Out | 29.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,948 |
| Average Volume | 21,295 |
| Open | 0.2398 |
| Previous Close | 0.2300 |
| Day's Range | 0.2206 - 0.2398 |
| 52-Week Range | 0.2000 - 0.7536 |
| Beta | 1.40 |
| RSI | 44.41 |
| Earnings Date | Jun 26, 2026 |
About Biotricity
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux and Biocore Pro, an integrated ECG device and software that utilizes wet electrodes for cardiac outpatient monitoring (COM) market; Biocore, a Holter and Extended Holter monitors for cardiac diagnostics; Biocare which su... [Read more]
Financial Performance
In fiscal year 2025, Biotricity's revenue was $13.79 million, an increase of 14.32% compared to the previous year's $12.06 million. Losses were -$11.94 million, -20.01% less than in 2024.
Financial StatementsNews
Biotricity Earnings Call Transcript: Q3 2026
Revenue grew 10.2% year-over-year to $4M, with gross margin rising to 81.5% and positive EBITDA for the third consecutive quarter. The company expects continued revenue growth and aims for net income profitability in 2026, driven by strong adoption of its cardiac monitoring solutions.
Biotricity Delivers Strong Q3 Fiscal 2026 Performance, Growing Revenue Momentum and Expanding EBITDA
REDWOOD CITY, CA, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to transforming chronic...
Biotricity to Announce Continued Growth in Fiscal 2026 Third Quarter Financial Results and Business Update Call on February 11th
Company continues to drive Revenue Growth, Margin Strength, Operational Efficiency, and continued positive EBITDA REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), ...
Biotricity Earnings Call Transcript: Q2 2026
Revenue grew 19% year-over-year to $3.9M, with gross margin rising to 81.9% and EBITDA positive for the second consecutive quarter. Strategic partnerships, product innovation, and commercial expansion are expected to drive continued growth and profitability.
Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Biotricity to Host Fiscal 2026 Second Quarter Financial Results and Business Update Call on November 14th
REDWOOD CITY, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Health-E Commerce® and Biotricity® Collaborate to Expand Remote Cardiac Monitoring with Bioheart® for Flexible Spending Account (FSA) and Health Savings Account (HSA) Users
New telehealth offering empowers consumers to use pre-tax healthcare funds at FSA Store® and HSA Store® to make heart health a part of everyday life with at-homemonitoring DALLAS and REDWOOD CITY, Cal...
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solu...
Biotricity Earnings Call Transcript: Q1 2026
Revenue grew 21% year-over-year to $3.9M, with gross margin rising to 80.5%. Achieved first-ever positive EBITDA of $333K and operating profit, while net loss narrowed significantly. Strategic partnerships and regulatory approvals support continued growth.
Biotricity Reinforces Growth Trajectory, Kicking Off Fiscal 2026 with Strong First Quarter Results Featuring Revenue Growth, Positive EBITDA and Improved Margins
REDWOOD CITY, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the lands...
Biotricity to Host Fiscal 2026 First Quarter Financial Results and Business Update Call on August 14th
Company to announce continued Revenue Growth, Improvements in Margins, Operational Efficiency, and a shift to positive EBITDA
Biotricity Delivers Strong Fiscal Year 2025 Results with Revenue Growth, Continued Margin Improvement, and Reduced Operating Expenses, Putting Profitability within Reach
REDWOOD CITY, CA, July 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company that offers innovative diagnostic, chronic di...
Biotricity to Host Fiscal 2025 Fourth Quarter Financial Results and Business Update Call on July 18th
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an in...
Biotricity Recognized by Financial Times as One of 2025's Fastest-Growing Companies in the Americas, Growing 256.4% Over the Period Analyzed
REDWOOD CITY, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) a leading Technology-as-a-Service (Taas) company specializing in cutting-edge diagnostic and chronic disease mana...
Biotricity Expands IP Portfolio & Strategy with 14 New Patents, Reinforcing Innovation & Leadership in Remote Monitoring, Diagnostics, & Chronic Disease Management
Biotricity's latest patents focus on a multi-biometric device platform that functions as both a patch and watch, advancing biometric monitoring solutions for remote patient care.
Biotricity Delivers Record Margins, Record Revenues, and Record Cashflows with 21.7% Year-Over-Year Sales Growth for its Third Quarter of Fiscal 2025
REDWOOD CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a top Technology-as-a-Service (TaaS) company that is redefining the healthcare i...
Biotricity Earnings Call Transcript: Q3 2025
Q3 2025 saw 21.7% revenue growth, record gross margins, and a 115% improvement in free cash flow. Strategic partnerships and new verticals are expanding market reach, with profitability and further margin gains expected as AI and international initiatives progress.
Biotricity Announces Cashflow Breakeven with Biggest Quarter in History and a Revenue Increase of 11%
REDWOOD CITY, Calif., Feb. 17, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor ...
Biotricity and B-Secur Partner to Launch the Most Comprehensive Device-Neutral Ambulatory Cardiac Monitoring Platform
REDWOOD CITY, Calif. and BELFAST, Northern Ireland , Jan. 15, 2025 /PRNewswire/ -- Biotricity Inc. (OTCQB:BTCY), a provider of remote cardiac monitoring solutions, and B-Secur, a leader in biosensing...
Biotricity Produces Largest Inventory in its History to Meet Accelerated Demand
Company Receives Capital Needed from its Term Lender and Existing Investors to Reach Profitability without any need for future financing. REDWOOD CITY, Calif.
Biotricity Achieves Positive Free Cash Flow Milestone
First Time in the Company's History REDWOOD CITY, Calif. , Dec. 3, 2024 /PRNewswire/ -- Biotricity Inc. (OTCQB: BTCY) ("Biotricity" or the "Company"), a Technology-as-a-Service (TaaS) company operatin...
Biotricity Earnings Call Transcript: Q2 2025
Q2 2025 saw 13% revenue growth, a 23% rise in gross profit, and a 57% reduction in net loss. Positive EBITDA was achieved for the first time, driven by operational efficiencies, strategic partnerships, and expanded market reach, with a clear path to profitability.
Biotricity Achieves Improved Margins and Efficiencies, and Year-Over-Year Sales Growth for Second Quarter of Fiscal Year 2025
REDWOOD CITY, Calif., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY) (“Biotricity” or the “Company”), a Technology-as-a-Service (TaaS) company operating in the remote cardiac monitor...
Biotricity to Host Second Quarter Fiscal Year 2025 Financial Results and Business Update Call on November 15th
Company to announce improvements in Margins, Operational Efficiency, and a shift to positive Adjusted EBITDA REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an i...
Biotricity Provides Updated Guidance for Earlier than Expected Path to Profitability due to Growing Revenues and Improving Margins
The company has achieved EBIDTA positive on a go-forward cash basis REDWOOD CITY, CA / ACCESSWIRE / October 3, 2024 / Biotricity Inc. (OTCQB:BTCY), an innovative Technology-as-a-Service (TaaS) company...